Obesity, Renal Insufficiency, Chronic, Time Restricted Feeding
Conditions
Keywords
time-restricted feeding, chronic kidney disease, obesity
Brief summary
Obesity is associated with glomerular hyperfiltration leading to renal impairment and is a risk factor for the progression of kidney disease.Weight loss can reduce proteinuria and improve eGFR.Intermittent fasting is safe and effective, and in addition to improving body shape and weight in obese patients, it can also improve glucolipid metabolism, reduce proteinuria, improve kidney function and delay the progression of kidney disease.
Detailed description
KDOQI clinical practice guideline for nutrition in chronic kidney disease (CKD) uses a low-protein diet to reduce renal impairment and delay progression. The current research hotspot is dietary intervention. Time-restricted feeding was used to intervene in the progression of CKD. It restrict the time of eating but not the eaten calories, which have a higher compliance and safety. Studies have shown that intermittent fasting in obese patients with CKD is not only reduce body weight, but also improves glycolipid metabolism, reduces proteinuria and delays the progression of kidney disease. Intermittent fasting is currently a scientific research hotspot, and there are few international studies on the implementation of intermittent fasting to delay the deterioration of renal function in obese CKD patients, and lack of data on Chinese patients, which has great research potential. Based on the above background, this study was conducted as an pilot clinical trial to explore the effects of intermittent fasting on obese patients with CKD and to observe its effectiveness, safety and compliance.
Interventions
BEHAVIORALTime-restricted feeding(TRF)
The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
It was non-randomized trial study design, two parallel groups were assigned to time-restricted feeding(TRF) and control group and to do the intervention for 12 weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65 years * CKD stage 3-4 and not on dialysis (eGFR: 15-59ml/min/1.73m2) * BMI ≥ 25 kg/m2 * Good reading and comprehension skills, simple smartphone operation and no communication difficulties * Signed informed consent
Exclusion criteria
* Pregnant and breastfeeding * End-stage diseases * Acute and active diseases such as gastrointestinal bleeding or acute infections, serious decompensation with diseases such as cirrhosis decompensation stage, malignant tumor, serious heart and lung diseases, severe primary diseases of hematopoietic system, severe hypertension (systolic blood pressure ≥200mmHg, diastolic blood pressure ≥120mmHg) and difficult to control blood pressure, within 3 months after major surgery, such as open surgery * Mental patients * Using medium-high doses of hormones and immunosuppressants * Participating in other researchers * Taking other dietary therapies, undergoing weight loss treatment * Vegetarian * Type 1 diabetes and type 2 diabetes using insulin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in eGFR (ml/min/1.73m2) | 12 weeks | eGFR at final visit - eGFR at initial visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in species of intestinal flora | 12 weeks | species of intestinal flora at final visit - species of intestinal flora at initial visit |
| Changes in triceps skin fold thickness (cm) | 12 weeks | triceps skin fold thickness at final visit - triceps skin fold thickness at initial visit |
| Changes in grip strength (kg) | 12 weeks | grip strength at final visit - grip strength at initial visit |
| Changes in fasting blood glucose (mmol/L) | 12 weeks | fasting blood glucose at final visit - fasting blood glucose at initial visit |
| Changes in serum creatinine (umol/L) | 12 weeks | serum creatinine at final visit - serum creatinine at initial visit |
| Changes in blood urea nitrogen (mmol/L) | 12 weeks | blood urea nitrogen at final visit - blood urea nitrogen at initial visit |
| Changes in serum uric acid (umol/L) | 12 weeks | serum uric acid at final visit - serum uric acid at initial visit |
| Changes in proteinuria creatinine ratio (g/g) | 12 weeks | proteinuria creatinine ratio at final visit - proteinuria creatinine ratio at initial visit |
| Changes in serum cystatin C (mg/L) | 12 weeks | serum cystatin C at final visit - serum cystatin C at initial visit |
| Changes in total urine urea in 24 hours (mmol/24h) | 12 weeks | total urine urea in 24 hours at final visit - total urine urea in 24 hours at initial visit |
| Changes in interleukin-6 (pg/mL) | 12 weeks | interleukin-6 at final visit - interleukin-6 at initial visit |
| Changes in tumor necrosis factor-α (pg/mL) | 12 weeks | tumor necrosis factor-α at final visit - tumor necrosis factor-α at initial visit |
| Changes in C-reactive protein (mg/L) | 12 weeks | C-reactive protein at final visit - C-reactive protein at initial visit |
| Changes in body weight (Kilograms) | 12 weeks | body weight at final visit - body weight at initial visit |
| Changes in waist circumference (cm) | 12 weeks | waist circumference at final visit - waist circumference at initial visit |
| Change in body mass index (kg/m2) | 12 weeks | body mass index at final visit - body mass index at initial visit |
| Changes in serum total cholesterol levels (mmol/L) | 12 weeks | serum total cholesterol levels at final visit - serum total cholesterol levels at initial visit |
| Changes in serum low density lipoprotein cholesterol levels (mmol/L) | 12 weeks | serum low density lipoprotein cholesterol levels at final visit - serum low density lipoprotein cholesterol levels at initial visit |
| Changes in serum triglyceride levels (mmol/L) | 12 weeks | serum triglyceride levels at final visit - serum triglyceride levels at initial visit |
| Changes in serum high density lipoprotein cholesterol levels (mmol/L) | 12 weeks | serum high density lipoprotein cholesterol levels at final visit - serum high density lipoprotein cholesterol levels at initial visit |
| Changes in serum albumin (g/L) | 12 weeks | serum albumin at final visit - serum albumin at initial visit |
| Changes in total serum protein (g/L) | 12 weeks | total serum protein at final visit - total serum protein at initial visit |
| Changes in fat free mass (kg) | 12 weeks | fat free mass at final visit - fat free mass at initial visit |
| Changes in body fat mass (kg) | 12 weeks | body fat mass at final visit - body fat mass at initial visit |
| Changes in percent body fat (%) | 12 weeks | percent body fat at final visit - percent body fat at initial visit |
| Changes in waist-hip ratio | 12 weeks | waist-hip ratio at final visit - waist-hip ratio at initial visit |
| Changes in soft lean mass (kg) | 12 weeks | soft lean mass at final visit - soft lean mass at initial visit |
| Changes in visceral fat area (cm2) | 12 weeks | visceral fat area at final visit - visceral fat area at initial visit |
| Changes in arm circumference (cm) | 12 weeks | arm circumference at final visit - arm circumference at initial visit |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in fatigue scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in satiety scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in gastrointestinal flatulence scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in nausea and vomiting scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in constipation scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in diarrhea scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in dry mouth and bitterness scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in dizziness and headache scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in irritability scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in anxiety scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in depression scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
| Changes in hunger scores | Weeks 6 and 12 | Assessed using Visual Analog Scales (VAS with a scale of 1-10) |
Countries
China
Outcome results
None listed